Back to News
Market Impact: 0.2
Regeneron Reports Long-Term Phase 3 Benefit For Libtayo In High-Risk CSCC
Source: Nasdaq
Healthcare & Biotech
Regeneron announced longer-term Phase 3 C-POST trial data, including nearly four years of follow-up, evaluating Libtayo (cemiplimab) as adjuvant treatment for patients with high-risk cutaneous squamous cell carcinoma. The provided article text does not report the trial results or their implications.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
Ticker Sentiment
REGN0.20
More News
- Regeneron extends Ebola treatment supply deal with US government
- J&J's potential 'game-changer' drug — plus, what Microsoft's mass buyouts mean
- Cramer: I asked some tech insiders what to buy. They surprisingly said this drug stock
- The excitement around Moderna’s cancer vaccine is cooling. Here’s why.
- Moderna CEO Sees Cancer Vaccines Working Beyond Melanoma
- Bottoms Says Georgia Needs Pause on New Data Centers